A novel fasting blood test for insulin resistance and prediabetes

Journal of Diabetes Science and Technology

Volumn 7, Issue 1, 2013, Pages 100-110

  Cobb, Jeff ^a   Gall, Walter ^a   Adam, Klaus Peter ^a   Nakhle, Pamela ^a   Button, Eric ^a   Hathorn, James ^a   Lawton, Kay ^a   Milburn, Michael ^a   Perichon, Regis ^a   Mitchell, Matthew ^a   Natali, Andrea ^b   Ferrannini, Ele ^b  

^a METABOLON INC   (United States)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Biomarkers; Insulin resistance; Metabolomics; Prediabetes; Quantose

Indexed keywords

GLUCOSE; INSULIN;

ADULT; ALGORITHM; ARTICLE; BLOOD SAMPLING; BODY MASS; CLAMP; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GOLD STANDARD; HOMEOSTASIS; HUMAN; HYPERINSULINEMIC EUGLYCEMIC CLAMP; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; VALIDATION STUDY; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; DIET RESTRICTION; METABOLISM; MIDDLE AGED;

ADULT; ALGORITHMS; AREA UNDER CURVE; BLOOD GLUCOSE; FASTING; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PREDIABETIC STATE;

EID: 84878253693     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681300700112     Document Type: Article

References (50)

1. Ferrannini E, Balkau B, Coppack SW, Dekker JM, Mari A, Nolan J, Walker M, Natali A, Beck-Nielsen H; RISC Investigators. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab. 2007;92(8):2885-92. (Pubitemid 47236346)
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607. (Pubitemid 19004941)
3. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279-90.
4. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214-23. (Pubitemid 9249478)
5. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab. 1998;83(8):2773-6. (Pubitemid 28493774)
6. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137(9):959-65. (Pubitemid 23191063)
7. Kim SH, Reaven GM. Insulin resistance and hyperinsulinemia: you can't have one without the other. Diabetes Care. 2008;31(7):1433-8.
8. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106(4):473-81. (Pubitemid 30666380)
9. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens. 1998;16(7):895-906. (Pubitemid 28367943)
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. (Pubitemid 15018832)
11. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-95. (Pubitemid 38680001)
12. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402-10. (Pubitemid 32269192)
13. Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J. A simple measure of insulin resistance. Lancet. 1995;346(8967):120-1.
14. Brady LM, Gower BA, Lovegrove SS, Williams CM, Lovegrove JA. Revised QUICKI provides a strong surrogate estimate of insulin sensitivity when compared with the minimal model. Int J Obes Relat Metab Disord. 2004;28(2):222-7. (Pubitemid 38223502)
15. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, Duncan AW. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24(3):460-4. (Pubitemid 32198413)
16. Disse E, Bastard JP, Bonnet F, Maitrepierre C, Peyrat J, Louche-Pelissier C, Laville M. A lipid-parameter-based index for estimating insulin sensitivity and identifying insulin resistance in a healthy population. Diabetes Metab. 2008;34(5):457-63.
17. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462-70. (Pubitemid 29418240)
18. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften T, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000;23(3):295-301. (Pubitemid 30131733)
19. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001;24(3):539-48. (Pubitemid 32198427)
20. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985;6(1):45-86.
21. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26(12):3320-5. (Pubitemid 37466894)
22. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294(1):E15-26.
23. Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, Ryals JA, Milburn MV, Nannipieri M, Camastra S, Natali A, Ferrannini E; RISC Study Group. Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One. 2010;5(5):e10883.
24. Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, Walker M, Ferrannini E; EGIR-RISC Study Group. The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia. 2004;47(3):566-70. (Pubitemid 38491256)
25. Ferrannini E, Natali A, Muscelli E, Nilsson PM, Golay A, Laakso M, Beck-Nielsen H, Mari A; RISC Investigators. Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. Diabetologia. 2011;54(6):1507-16.
26. Lawton KA, Berger A, Mitchell M, Milgram KE, Evans AM, Guo L, Hanson RW, Kalhan SC, Ryals JA, Milburn MV. Analysis of the adult human plasma metabolome. Pharmacogenomics. 2008;9(4):383-97. (Pubitemid 351803924)
27. Eckhart AD, Beebe K, Milburn M. Metabolomics as a key integrator for "omic" advancement of personalized medicine and future therapies. Clin Transl Sci. 2012;5(3):285-8.
28. R Development Core Team. The R project for statistical computing. http://www.R-project.org/.
29. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
30. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-45.
31. Friedrich N. Metabolomics in diabetes research. J Endocrinol. 2012;215(1):29-42.
32. Hyötyläinen T, Mattila I, Wiedmer SK, Koivuniemi A, Taskinen MR, Yki-Järvinen H, Orešič M. Metabolomic analysis of polar metabolites in lipoprotein fractions identifies lipoprotein-specific metabolic profiles and their association with insulin resistance. Mol Biosyst. 2012;8(10):2559-65.
33. Milburn M, Lawton K. Application of metabolomics to diagnosis of insulin resistance. Annu Rev Med. Forthcoming 2013.
34. Woo YC, Tso AW, Xu A, Law LS, Fong CH, Lam TH, Lo SV, Wat NM, Cheung BM, Lam KS. Combined use of serum adiponectin and tumor necrosis factor-alpha receptor 2 levels was comparable to 2-hour post-load glucose in diabetes prediction. PLoS One. 2012;7(5):e36868.
35. Urdea M, Kolberg J, Wilber J, Gerwien R, Moler E, Rowe M, Jorgensen P, Hansen T, Pedersen O, Jørgensen T, Borch-Johnsen K. Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99). J Diabetes Sci Technol. 2009;3(4):748-55.
36. Herder C, Karakas M, Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther. 2011;90(1):52-66.
37. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011;18(2):139-43.
38. Landaas S. The formation of 2-hydroxybutyric acid in experimental animals. Clin Chim Acta. 1975;58(1):23-32.
39. Rubio-Aliaga I, de Roos B, Duthie SJ, Crosley LK, Mayer C, Horgan G, Colquhoun IJ, Le Gall G, Huber F, Kremer W, Rychlik M, Wopereis S, van Ommen B, Schmidt G, Heim C, Bouwman FG, Mariman EC, Mulholland F, Johnson IT, Polley AC, Elliott RM, Daniel H. Metabolomics of prolonged fasting in humans reveals new catabolic markers. Metabolomics. 2011;7(3):375-87.
40. Cunningham TJ, Yao L, Lucena A. Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic properties. J Inflamm (Lond). 2008;5:17.
41. Soga T, Ohishi T, Matsui T, Saito T, Matsumoto M, Takasaki J, Matsumoto S, Kamohara M, Hiyama H, Yoshida S, Momose K, Ueda Y, Matsushime H, Kobori M, Furuichi K. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005;326(4):744-51. (Pubitemid 39655983)
42. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012;15(5):606-14
43. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448-53.
44. Wang T, Bi Y, Xu M, Huang Y, Xu Y, Li X, Wang W, Ning G. Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese. Endocrine. 2011;40(1):109-16.
45. Ferrannini E, Natali A, Camastra S, Nannipieri M, Mari A, Adam K-P, Milburn MV, Kastenmüller G, Adamski J, Tuomi T, Lyssenko V, Groop L, Gall WE. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes. Epub 2012 Nov 16.
46. Carnethon MR, De Chavez PJ, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, Golden SH, Liu K, Mukamal KJ, Campbell-Jenkins B, Dyer AR. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308(6):581-90.
47. Staten MA, Stern MP, Miller WG, Steffes MW, Campbell SE; Insulin Standardization Workgroup. Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care. Diabetes Care. 2010;33(1):205-6.
48. Rodríguez-Cabaleiro D, Van Uytfanghe K, Stove V, Fiers T, Thienpont LM. Pilot study for the standardization of insulin immunoassays with isotope dilution liquid chromatography/tandem mass spectrometry. Clin Chem. 2007;53(8):1462-9. (Pubitemid 47206342)
49. Miller WG, Thienpont LM, Van Uytfanghe K, Clark PM, Lindstedt P, Nilsson G, Steffes MW; Insulin Standardization Work Group. Toward standardization of insulin immunoassays. Clin Chem. 2009;55(5):1011-8.
50. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379(9833):2243-51.